` ACET (Adicet Bio Inc) vs S&P 500 Comparison - Alpha Spread

ACET
vs
S&P 500

Over the past 12 months, ACET has underperformed S&P 500, delivering a return of -55% compared to the S&P 500's 10% growth.

Stocks Performance
ACET vs S&P 500

Loading
ACET
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
ACET vs S&P 500

Performance Gap Between ACET and GSPC
HIDDEN
Show

Performance By Year
ACET vs S&P 500

Loading
ACET
S&P 500
Add Stock

Competitors Performance
Adicet Bio Inc vs Peers

S&P 500
ACET
ABBV
AMGN
GILD
VRTX
Add Stock

Adicet Bio Inc
Glance View

Market Cap
55.5m USD
Industry
Biotechnology

Adicet Bio, Inc. is a biotechnology company, which engages in the design and development of off-the-shelf allogeneic gamma delta T cell therapies for cancer and other diseases. The company is headquartered in Boston, Massachusetts and currently employs 86 full-time employees. The company went IPO on 2018-01-26. The company is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CAR) and T cell receptor-like antibodies (TCRL), to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response and improve persistence for durable activity in patients. Its lead product candidate, ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is under Phase I study for the treatment of Non-Hodgkin's Lymphoma. Its pipeline also includes ADI-002, an allogeneic gamma delta CAR-T cell therapy expressing a GPC3-targeted CAR and a cell intrinsic soluble form of interluiken-15, for the treatment of solid tumors. In addition, it is engaged in discovery and preclinical stage activities of its pipeline of product candidates for both hematological malignancies and solid tumors.

ACET Intrinsic Value
Not Available
Back to Top